全文获取类型
收费全文 | 99088篇 |
免费 | 7934篇 |
国内免费 | 273篇 |
专业分类
耳鼻咽喉 | 1179篇 |
儿科学 | 2777篇 |
妇产科学 | 1617篇 |
基础医学 | 13772篇 |
口腔科学 | 1251篇 |
临床医学 | 10680篇 |
内科学 | 20780篇 |
皮肤病学 | 1097篇 |
神经病学 | 9261篇 |
特种医学 | 3814篇 |
外国民族医学 | 3篇 |
外科学 | 15278篇 |
综合类 | 1456篇 |
一般理论 | 119篇 |
预防医学 | 8077篇 |
眼科学 | 2322篇 |
药学 | 6919篇 |
1篇 | |
中国医学 | 100篇 |
肿瘤学 | 6792篇 |
出版年
2023年 | 729篇 |
2022年 | 1141篇 |
2021年 | 2678篇 |
2020年 | 1505篇 |
2019年 | 2453篇 |
2018年 | 2811篇 |
2017年 | 2004篇 |
2016年 | 2125篇 |
2015年 | 2510篇 |
2014年 | 3628篇 |
2013年 | 4666篇 |
2012年 | 7335篇 |
2011年 | 7634篇 |
2010年 | 4164篇 |
2009年 | 3650篇 |
2008年 | 6160篇 |
2007年 | 6393篇 |
2006年 | 5985篇 |
2005年 | 5963篇 |
2004年 | 5366篇 |
2003年 | 4948篇 |
2002年 | 4541篇 |
2001年 | 1225篇 |
2000年 | 1079篇 |
1999年 | 1123篇 |
1998年 | 1049篇 |
1997年 | 787篇 |
1996年 | 708篇 |
1995年 | 643篇 |
1994年 | 594篇 |
1993年 | 581篇 |
1992年 | 774篇 |
1991年 | 715篇 |
1990年 | 649篇 |
1989年 | 591篇 |
1988年 | 564篇 |
1987年 | 551篇 |
1986年 | 561篇 |
1985年 | 572篇 |
1984年 | 518篇 |
1983年 | 430篇 |
1982年 | 450篇 |
1981年 | 404篇 |
1980年 | 324篇 |
1979年 | 410篇 |
1978年 | 345篇 |
1977年 | 310篇 |
1976年 | 245篇 |
1975年 | 243篇 |
1973年 | 237篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
3.
Triposkiadis Filippos Xanthopoulos Andrew Skoularigis John Starling Randall C. 《Heart failure reviews》2022,27(6):1991-2003
Heart Failure Reviews - The nitric oxide (NO)–guanylate cyclase (GC)–cyclic guanosine monophosphate (cGMP) pathway plays an important role in cardiovascular, pulmonary and renal... 相似文献
4.
Marike Gabrielson Mattias Hammarström Magnus Bäcklund Jenny Bergqvist Kristina Lång Ann H Rosendahl Signe Borgquist Roxanna Hellgren Kamila Czene Per Hall 《International journal of cancer. Journal international du cancer》2023,152(11):2362-2372
Tamoxifen prevents recurrence of breast cancer and is suggested for preventive risk-reducing therapy. Tamoxifen reduces mammographic density, a proxy for therapy response, but little is known about its effects in remodelling normal breast tissue. Our study, a substudy within the double-blinded dose-determination trial KARISMA, investigated tamoxifen-specific changes in breast tissue composition and histological markers in healthy women. We included 83 healthy women randomised to 6 months daily intake of 20, 10, 5, 2.5, 1 mg of tamoxifen or placebo. The groups were combined to “no dose” (0-1 mg), “low-dose” (2.5-5 mg) or “high-dose” (10-20 mg) of tamoxifen. Ultrasound-guided biopsies were collected before and after tamoxifen exposure. In each biopsy, epithelial, stromal and adipose tissues was quantified, and expression of epithelial and stromal Ki67, oestrogen receptor (ER) and progesterone receptor (PR) analysed. Mammographic density using STRATUS was measured at baseline and end-of-tamoxifen-exposure. We found that different doses of tamoxifen reduced mammographic density and glandular-epithelial area in premenopausal women and associated with reduced epithelium and increased adipose tissue. High-dose tamoxifen also decreased epithelial ER and PR expressions in premenopausal women. Premenopausal women with the greatest reduction in proliferation also had the greatest epithelial reduction. In postmenopausal women, high-dose tamoxifen decreased the epithelial area with no measurable density decrease. Tamoxifen at both low and high doses influences breast tissue composition and expression of histological markers in the normal breast. Our findings connect epithelial proliferation with tissue remodelling in premenopausal women and provide novel insights to understanding biological mechanisms of primary prevention with tamoxifen. 相似文献
5.
6.
7.
Xin Yi Wong Andrew Qi Jun Lim Qianyu Shen John Whay Kuang Chia Min Hoe Chew Wah Siew Tan 《Current medical research and opinion》2020,36(10):1677-1686
Abstract
Objective
Ras wild-type metastatic colorectal cancers (mCRC) may be treated with anti-vascular endothelial growth factor (VEGF) or anti-epidermal growth factor receptor (EGFR) agents. We aim to estimate patients’ preferences for mCRC treatment and relative importance of cost, efficacy improvement, avoidance of side effects and therapy convenience, and relative uptake between profiles that resemble Bevacizumab (anti-VEGF) and Cetuximab (anti-EGFR), two commonly prescribed mCRC targeted therapies. 相似文献8.
Caroline E. Sloan Judy Zhong Dinushika Mohottige Rasheeda Hall Clarissa J. Diamantidis Leight E. Boulware Virginia Wang 《Seminars in dialysis》2020,33(6):440-448
Caring for patients with end-stage kidney disease (ESKD) in the United States is challenging, due in part to the complex epidemiology of the disease's progression as well as the ways in which care is delivered. As CKD progresses toward ESKD, the number of comorbidities increases and care involves multiple healthcare providers from multiple subspecialties. This occurs in the context of a fragmented US healthcare delivery system that is traditionally siloed by provider specialty, organization, as well as systems of payment and administration. This article describes the role of care fragmentation in the delivery of optimal ESKD care and identifies research gaps in the evidence across the continuum of care. We then consider the impact of care fragmentation on ESKD care from the patient and health system perspectives and explore opportunities for system-level interventions aimed at improving care for patients with ESKD. 相似文献
9.